Ophthalmologica

Original Paper

Long-Term Real-Life Efficacy and Safety of Repeated Ozurdex® Injections and Factors Associated with Macular Edema Resolution after Retinal Vein Occlusion: The REMIDO 2 Study

Pommier S.a · Meyer F.a · Guigou S.a · Barthelemy T.a · Gobert F.a · Hajjar C.a · Merite P.-Y.a · Parrat E.a · Rouhette H.a · Matonti F.a-c

Author affiliations

aCollectif P1.5, Mougins, bOphthalmology Department, Aix-Marseille University, Hôpital Nord, and cTimone Neuroscience Institute, Aix-Marseille University, Marseille, France

Keywords: DexamethasoneRanibizumabOptical coherence tomographyOzurdex® injectionMacular edemaRetinal vein occlusionIntravitreal implant

Related Articles for ""
Ophthalmologica 2016;236:186-192
https://doi.org/10.1159/000452896

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 12, 2016
Accepted: October 26, 2016
Published online: December 08, 2016
Issue release date: January 2017

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 3

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Abstract

Purpose: The objective was to study long-term real-life efficacy and safety of repeated Ozurdex® injections and factors associated with macular edema (ME) resolution after retinal vein occlusion. Methods: Patients with ME after retinal vein occlusion, receiving Ozurdex®, were included to assess the following endpoints: visual acuity and central retinal thickness, retreatment, number of injections, side effects and ME resolution. ME resolution was defined as permanent discontinuation of intravitreal injections (IVTs) for at least 6 months after the last IVT. Results: A total of 94 eyes were included with an average of 2.6 IVTs (max 6 IVTs). 58.6% of patients gained ≥15 letters and 51.1% of patients showed ME resolution. Among the resolved patients, 64.6% were treatment-naïve, 60.4% had branch retinal vein occlusion, and 78.1% gained ≥15 letters. Conclusions: Ozurdex® seemed to be a valuable treatment which may allow to achieve long-term anatomical and functional improvements and ME resolution with a minimum number of IVTs.

© 2016 S. Karger AG, Basel



Related Articles:

References

  1. Yau JWY, Lee P, Wong TY, Best J, Jenkins A: Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008;38:904-910.
  2. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-319.e1.
  3. Laouri M, Chen E, Looman M, Gallagher M: The burden of disease of retinal vein occlusion: review of the literature. Eye Lond Engl 2011;25:981-988.
  4. Haller JA, Bandello F, Belfort RJ, Blumenkranz MS, Gillies M, Heier J, et al: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-2460.
  5. Haller JA, Bandello F, Belfort RJ, Blumenkranz MS, Gillies M, Heier J, et al: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.e3.
  6. Hahn P, Fekrat S: Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 2012;23:175-181.
  7. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, et al: Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 2013;229:21-25.
  8. Matonti F, Meyer F, Guigou S, Barthelemy T, Dumas S, Gobert F, et al: Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol (Copenh) 2013;91:e584-e586.
  9. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A: Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye Lond Engl 2013;27:65-71.
  10. Proença Pina J, Turki K, Labreuche J, Duhamel A, Tran THC: Efficacy and safety in retinal vein occlusion treated with at least three consecutive intravitreal dexamethasone implants. J Ophthalmol 2016;2016:6016491.
  11. Bakri SJ, Omar AF, Iezzi R, Kapoor KG: Evaluation of multiple dexamethasone intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 2016;36:552-557.
  12. Capone A, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, et al: Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 2014;34:342-351.
  13. Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li X-Y, Cui H, et al: Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015;15:150.
  14. Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-1914.
  15. Matonti F, Hoffart L, Baeteman C, Denis D: Repeated treatment for macular edema in vein occlusion by intravitreal implant of dexamethasone. Case Rep Ophthalmol 2012;3:339-342.
  16. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
  17. Roth DB, Cukras C, Radhakrishnan R, Feuer WJ, Yarian DL, Green SN, et al: Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surg Lasers Imaging 2008;39:446-454.
  18. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
  19. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-1128.
  20. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al: Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121:209-219.
  21. Altunel O, Göktaş A, Duru N, Özköse A, Arifoğlu HB, Ataş M: The effect of age on dexamethasone intravitreal implant (Ozurdex®) response in macular edema secondary to branch retinal vein occlusion. Semin Ophthalmol 2016:1-6.
  22. Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, et al: Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study. J Fr Ophtalmol 2014;37:480-485.
  23. Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, et al: Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2014;24:1-9.
  24. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM: Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996;103:551-560.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 12, 2016
Accepted: October 26, 2016
Published online: December 08, 2016
Issue release date: January 2017

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 3

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2016, Vol.236, No. 4

January 2017

Article

Recommend This
Additional Information

An abstract of the article has been presented previously at a Poster session during the 2014 EVER congress in Nice, France.
TOP